MRI showed more than 90% sensitivity in detecting nasopharyngeal carcinoma (NPC), surpassing endoscopy’s detection rate of 65.6% over a 5-year period. MRI particularly excelled in identifying ...

A gene based model using nasopharyngeal carcinoma biomarkers AURKA and BUB1 accurately predicts survival and demonstrates ...

After radiation therapy, certain cancer patients face a lingering question: Is a troubling lesion a return of the cancer, or ...

The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical ...

From January 12 to 15, 2026, the 44th J.P. Morgan Healthcare Conference (JPMHC) was held in San Francisco, California, USA. Dr. Ge Michael, President and CEO of Sichuan Kelun-Biotech Biopharmaceutical ...

The Hooks drop their Preseason All-Star Team for high school baseball and softball. Check out the players to watch in 4A-5A ...

Loqtorzi (toripalimab) showed significant improvement in progression-free survival for acral melanoma compared to standard chemotherapy in a phase 3 trial. Acral melanoma, a rare and aggressive ...

-Data show CCR8 target is present with high prevalence and density in many solid tumors- ...